StephenPaulBergerMD

PubMed

• 9 citations
  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.
  Nirmal Bhide, David Lindenbach, Margaret A. Surrena, Adam A. Goldenberg, Christopher Bishop, S. Paul Berger, Melanie A. Paquette> ;Psychopharmacology. 2013 Feb 7
• Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
  Paquette, M. A., Martinez, A. A., Macheda, T., Meshul, C. K., Johnson, S. W., Berger, S. P., Giuffrida, A.> ;Eur J Neurosci. 2012 Nov
• 25 citations
  MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
  Melanie A. Paquette, Akari M. Anderson, Jason R. Lewis, Charles K. Meshul, Steven W. Johnson, S. Paul Berger> ;Neuropharmacology. 2010 Jun 1
• 68 citations
  Post-retrieval disruption of a cocaine conditioned place preference by systemic and intrabasolateral amygdala β2- and α1-adrenergic antagonists
  Rick E. Bernardi, Andrey E. Ryabinin, S. Paul Berger, K. Matthew Lattal> ;Learning & Memory. 2009 Dec 1
• 28 citations
  Modafinil reinstates a cocaine conditioned place preference following extinction in rats.
  Rick E. Bernardi, Jason R. Lewis, K. Matthew Lattal, S. Paul Berger> ;Behavioural Brain Research. 2009 Dec 1
• 24 citations
  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism
  Melanie A. Paquette, Katherine Foley, Elizabeth G. Brudney, Charles K. Meshul, Steven W. Johnson, S. Paul Berger> ;Psychopharmacology. 2009 Mar 13
• Brain science and addiction
  S. Paul Berger> ;Lancet. 2008 Oct 11
• 17 citations
  Sigma ligands, but not N-methyl-D-aspartate antagonists, reduce levodopa-induced dyskinesias.
  Melanie A. Paquette, Elizabeth G. Brudney, Daniel B. Putterman, Charles K. Meshul, Steven W. Johnson, Stephen Paul Berger> ;Neuroreport. 2008 Jan 8
• 4 citations
  Old laws stop drugs being used in valuable new ways
  S. Paul Berger> ;Nature. 2007 Oct 25
• 25 citations
  Anisomycin disrupts a contextual memory following reactivation in a cocaine-induced locomotor activity paradigm.
  Rick E. Bernardi, K. Matthew Lattal, S. Paul Berger> ;Behavioral Neuroscience. 2007 Feb 1
• 24 citations
  Injection of oxotremorine in nucleus accumbens shell reduces cocaine but not food self-administration in rats.
  Gregory P. Mark, Anthony E. Kinney, Michele C. Grubb, Xiaoman Zhu, Deborah A. Finn, Sarah L. Mader, S. Paul Berger, Anita J. Bechtholt> ;Brain Research. 2006 Dec 6
• 100 citations
  Postretrieval propranolol disrupts a cocaine conditioned place preference
  Rick E. Bernardi, Kennon M. Lattal, Stephen Paul Berger> ;Neuroreport. 2006 Sep 18
• 51 citations
  A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence
  S. Paul Berger, Theresa Winhusen, Eugene Somoza, Judy M. Harrer, Juris P. Mezinskis, Deborah B. Leiderman, Margaret A. Montgomery, R. Jeffrey Goldsmith, Daniel A. Bloc...> ;Addiction. 2005 Mar 1
• 8 citations
  Fluoxetine Attenuates Adrenocortical but Not Subjective Responses to Cocaine Cues
  Steven L. Batki, S. Paul Berger> ;The American Journal of Drug and Alcohol Abuse. 2004 Jan 1
• 27 citations
  Altered behavioral response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration.
  Neil M. Richtand, Jeffrey A. Welge, Beth Levant, Aaron D Logue, Scott Hayes, Laurel M. Pritchard, Thomas D. Geracioti, Lique M. Coolen, S. Paul Berger> ;Neuropsychopharmacology. 2003 Apr 16
• 60 citations
  7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment.
  Laurel M. Pritchard, Aaron D Logue, Scott Hayes, Jeffrey A. Welge, Ming Xu, Jianhua Zhang, S. Paul Berger, Neil M. Richtand> ;Neuropsychopharmacology. 2003 Jan 1
• Evidence for the involvement of cyclooxygenase activity in the development of cocaine sensitization.
  Reid MS, Ho LB, Hsu K, Fox L, Tolliver BK, Adams JU, Franco A, Berger SP> ;Pharmacol. Biochem. Behav.. 2002-01-01
• 115 citations
  D3 dopamine receptor, behavioral sensitization, and psychosis.
  Neil M. Richtand, Stephen C. Woods, S. Paul Berger, Stephen M. Strakowski> ;Neuroscience and Biobehavioral Reviews. 2001 Jul 1
• The mineralocorticoid receptor expression in the mouse CNS is conserved during development.
  Kretz O, Schmid W, Berger S, Gass P> ;Neuroreport. 2001-05-08
• Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice.
  Gass P, Kretz O, Wolfer DP, Berger S, Tronche F, Reichardt HM, Kellendonk C, Lipp HP, Schmid W, Schütz G> ;EMBO Rep.. 2000-11-01
• Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: neuropharmacological characterization.
  Reid MS, Fox L, Ho LB, Berger SP> ;Synapse. 2000-02-01
• Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo.
  Tolliver BK, Newman AH, Katz JL, Ho LB, Fox LM, Hsu K, Berger SP> ;J. Pharmacol. Exp. Ther.. 1999-04-01
• Necessary role for ventral tegmental area adenylate cyclase and protein kinase A in induction of behavioral sensitization to intraventral tegmental area amphetamine.
  Tolliver BK, Ho LB, Fox LM, Berger SP> ;J. Pharmacol. Exp. Ther.. 1999-04-01
• A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects.
  Reid MS, Mickalian JD, Delucchi KL, Berger SP> ;Neuropsychopharmacology. 1999-03-01
• Behavioral and neurochemical components of nicotine sensitization following 15-day pretreatment: studies on contextual conditioning.
  Reid MS, Ho LB, Berger SP> ;Behav Pharmacol. 1998-03-01
• Join now to see all